Zai Lab Limited ZLAB

Company Overview

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for oncology, autoimmune disorders, infectious diseases, and neuroscience. The company operates primarily in the biotechnology and specialty pharmaceutical industries, with a strategic emphasis on bringing innovative global medicines to patients in China and other Asian markets while also advancing internally developed assets. Its business model combines in-licensed therapies from multinational pharmaceutical partners with proprietary research and development programs.

The company’s primary revenue drivers include product sales from commercialized therapies, milestone payments, and collaboration agreements. Key marketed products and development programs span areas such as lung cancer, ovarian cancer, breast cancer, gastric cancer, epilepsy, and chronic inflammatory diseases. Zai Lab was founded in 2014 by Samantha Du, who established the company to bridge innovative global drug development with unmet medical needs in Greater China. Since its founding, the company has evolved from a licensing-focused biotech into an integrated biopharmaceutical company with commercial infrastructure, manufacturing capabilities, and internal discovery platforms.